Intranasal vaccination with probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides elicits mucosal immunity

1. Collaborators, G. B. D. A. R Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 2221–2248 (2022).

   Google Scholar 

2. Shi, T. et al. Global and regional burden of hospital admissions for pneumonia in older adults: a systematic review and meta-analysis. J. Infect. Dis. 222, S570–S576 (2020).

   Google Scholar 

3. LeBlanc, J. J. et al. Burden of vaccine-preventable pneumococcal disease in hospitalized adults: a Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. Vaccine 35, 3647–3654 (2017).

   Google Scholar 

4. Yu, J. et al. New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B. Microbiol. Spectr. 13, e0244324 (2025).

   Google Scholar 

5. Ganaie, F. et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. mBio 11, https://doi.org/10.1128/mBio.00937-20 (2020).

6. Ganaie, F. A. et al. Discovery and characterization of pneumococcal serogroup 36 capsule subtypes, serotypes 36A and 36B. J. Clin. Microbiol. 61, e0002423 (2023).

   Google Scholar 

7. Collaborators, G. B. D. L. R. I Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 18, 1191–1210 (2018).

   Google Scholar 

8. Kalizang’oma, A. et al. Clonal expansion of a Streptococcus pneumoniae serotype 3 capsule variant sequence type 700 with enhanced vaccine escape potential after 13-valent pneumococcal conjugate vaccine introduction. J. Infect. Dis. 230, e189–e198 (2024).

   Google Scholar 

9. Candeias, C. et al. Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: a cross-sectional study. Vaccine 42, 126219 (2024).

   Google Scholar 

10. von Mollendorf, C. & Ong-Lim, A. L. T. How have pneumococcal conjugate vaccines changed the pneumococcal disease landscape?. Lancet Infect. Dis. 25, 367–369 (2025).

    Google Scholar 

11. Ranjbar, R. & Alam, M. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Evid. Based Nurs. https://doi.org/10.1136/ebnurs-2022-103540 (2023).

12. Hyams, C. et al. Serotype distribution and disease severity in adults hospitalized with Streptococcus pneumoniae infection, Bristol and Bath, UK, 2006‒2022. Emerg. Infect. Dis. 29, 1953–1964 (2023).

    Google Scholar 

13. Li, L. et al. Epidemiological characteristics and antibiotic resistance mechanisms of Streptococcus pneumoniae: an updated review. Microbiol. Res. 266, 127221 (2023).

    Google Scholar 

14. Kobayashi, M. et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb. Mortal Wkly Rep. 73, 793–798 (2024).

    Google Scholar 

15. Rappuoli, R. Glycoconjugate vaccines: principles and mechanisms. Sci. Transl. Med. 10, https://doi.org/10.1126/scitranslmed.aat4615 (2018).

16. Chen, C. et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob. Health 7, e58–e67 (2019).

    Google Scholar 

17. Belshe, R. B. et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin. Infect. Dis. 39, 920–927 (2004).

    Google Scholar 

18. Eiden, J. et al. Intranasal M2SR (M2-deficient single replication) H3N2 influenza vaccine provides enhanced mucosal and serum antibodies in adults. J. Infect. Dis. 227, 103–112 (2022).

    Google Scholar 

19. Babu, T. M., Jackson, L. A. & El Sahly, H. M. Next-generation SARS-CoV-2 vaccine formulations and alternative routes of administration. J. Infect. Dis. 231, 44–48 (2025).

    Google Scholar 

20. Chu, K. et al. A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years. NPJ Vaccines 10, 50 (2025).

    Google Scholar 

21. Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739–748 (2022).

    Google Scholar 

22. Hirayama, S. & Nakao, R. Glycine induction method: effective production of immunoactive bacterial membrane vesicles with low endotoxin content. Methods Mol. Biol. 2414, 207–226 (2022).

    Google Scholar 

23. Hirayama, S. & Nakao, R. Glycine significantly enhances bacterial membrane vesicle production: a powerful approach for isolation of LPS-reduced membrane vesicles of probiotic Escherichia coli. Microb. Biotechnol. 13, 1162–1178 (2020).

    Google Scholar 

24. Nakao, R. et al. A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles. NPJ Vaccines 7, 153 (2022).

    Google Scholar 

25. Musher, D. M. et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J. Infect. Dis. 201, 516–524 (2010).

    Google Scholar 

26. van Werkhoven, C. H., Huijts, S. M., Bolkenbaas, M., Grobbee, D. E. & Bonten, M. J. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin. Infect. Dis. 61, 1835–1838 (2015).

    Google Scholar 

27. Thevaranjan, N. et al. Streptococcus pneumoniae colonization disrupts the microbial community within the upper respiratory tract of aging mice. Infect. Immun. 84, 906–916 (2016).

    Google Scholar 

28. Cubas, R. et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J. Immunother. 32, 118–128 (2009).

    Google Scholar 

29. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159–1164 (2007).

    Google Scholar 

30. Wilson, J. T. A sweeter approach to vaccine design. Science 363, 584–585 (2019).

    Google Scholar 

31. Munoz-Wolf, N. et al. Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles. Cell Rep. Med. 4, 100899 (2023).

    Google Scholar 

32. Degn, S. E. & Tolar, P. Towards a unifying model for B-cell receptor triggering. Nat. Rev. Immunol. 25, 77–91 (2025).

    Google Scholar 

33. Tolar, P. & Pierce, S. K. Unveiling the B cell receptor structure. Science 377, 819–820 (2022).

    Google Scholar 

34. Olivo-Martinez, Y. et al. Modulation of serotonin-related genes by extracellular vesicles of the probiotic Escherichia coli Nissle 1917 in the interleukin-1beta-induced inflammation model of intestinal epithelial cells. Int. J. Mol. Sci. 25, https://doi.org/10.3390/ijms25105338 (2024).

35. Canas, M. A., Fabrega, M. J., Gimenez, R., Badia, J. & Baldoma, L. Outer membrane vesicles from probiotic and commensal Escherichia coli activate NOD1-mediated immune responses in intestinal epithelial cells. Front. Microbiol. 9, 498 (2018).

    Google Scholar 

36. Jerving, S. The long road ahead for COVID-19 vaccination in Africa. Lancet 398, 827–828 (2021).

    Google Scholar 

37. Loyo, E. S. L., Gonzalez, M. J. & Esparza, J. Venezuela is collapsing without COVID-19 vaccines. Lancet 397, 1806 (2021).

    Google Scholar 

38. Li, X. et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet 397, 398–408 (2021).

    Google Scholar 

39. Zhang, J. R. et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 102, 827–837 (2000).

    Google Scholar 

40. Briles, D. E. et al. PspA and PspC: their potential for use as pneumococcal vaccines. Microb. Drug Resist. 3, 401–408 (1997).

    Google Scholar 

41. Hammerschmidt, S., Talay, S. R., Brandtzaeg, P. & Chhatwal, G. S. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol. Microbiol. 25, 1113–1124 (1997).

    Google Scholar 

42. Lu, L., Lamm, M. E., Li, H., Corthesy, B. & Zhang, J. R. The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4. J. Biol. Chem. 278, 48178–48187 (2003).

    Google Scholar 

43. Iovino, F. et al. Pneumococcal meningitis is promoted by single cocci expressing pilus adhesin RrgA. J. Clin. Investig. 126, 2821–2826 (2016).

    Google Scholar 

44. Iovino, F. et al. pIgR and PECAM-1 bind to pneumococcal adhesins RrgA and PspC mediating bacterial brain invasion. J. Exp. Med. 214, 1619–1630 (2017).

    Google Scholar 

45. Renegar, K. B., Small, P. A. Jr, Boykins, L. G. & Wright, P. F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173, 1978–1986 (2004).

    Google Scholar 

46. Renegar, K. B., Jackson, G. D. & Mestecky, J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J. Immunol. 160, 1219–1223 (1998).

    Google Scholar 

47. Suzuki, T. et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc. Natl. Acad. Sci. USA 112, 7809–7814 (2015).

    Google Scholar 

48. Saito, S. et al. IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody. PLoS Pathog. 15, e1007427 (2019).

    Google Scholar 

49. Keller, L. E., Robinson, D. A. & McDaniel, L. S. Nonencapsulated Streptococcus pneumoniae: emergence and pathogenesis. mBio 7, e01792 (2016).

    Google Scholar 

50. Nissle, A. Über die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora. Dtsch. Med. Wochenschr. 42, 1181–1184 (1916).

    Google Scholar 

51. Wang, R. F. & Kushner, S. R. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 100, 195–199 (1991).

    Google Scholar 

52. Price, N. L. et al. Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci. Rep. 6, 24931 (2016).

    Google Scholar 

53. Imohl, M., Reinert, R. R., Ocklenburg, C. & van der Linden, M. Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J. Clin. Microbiol. 48, 1291–1296 (2010).

    Google Scholar 

54. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal. Biochem. 72, 248–254 (1976).

    Google Scholar 

55. Percie du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 18, e3000410 (2020).

    Google Scholar 

56. Asahi, Y. et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol. 168, 2930–2938 (2002).

    Google Scholar 

57. Abdus Salam, M. et al. Establishment of an animal model using recombinant NOD.B10.D2 mice to study initial adhesion of oral streptococci. Clin. Diagn. Lab. Immunol. 11, 379–386 (2004).

    Google Scholar 

58. Kawai, S., Takagi, Y., Kaneko, S. & Kurosawa, T. Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp. Anim. 60, 481–487 (2011).

    Google Scholar 

59. Bai, D., Nakao, R., Ito, A., Uematsu, H. & Senpuku, H. Immunoreactive antigens recognized in serum samples from mice intranasally immunized with Porphyromonas gingivalis outer membrane vesicles. Pathog. Dis. 73, https://doi.org/10.1093/femspd/ftu006 (2015).

60. Henckaerts, I., Durant, N., De Grave, D., Schuerman, L. & Poolman, J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 25, 2518–2527 (2007).

    Google Scholar 

61. Romero-Steiner, S. et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccine Immunol. 13, 165–169 (2006).

    Google Scholar 

62. Kim, K. H., Yu, J. & Nahm, M. H. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin. Diagn. Lab. Immunol. 10, 616–621 (2003).

    Google Scholar 

63. Burton, R. L. & Nahm, M. H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin. Vaccine Immunol. 13, 1004–1009 (2006).

    Google Scholar 

64. Nahm, M. H. & Burton, R. L. Protocol for multiplexed opsonophagocytic killing assay (UAB-MOPA) for antibodies against Streptococcus pneumoniae Protoc. UAB-MOPA 1–43 Version E.02, https://www.vaccine.uab.edu/index.html (2014).

Download references